GFS Advisors LLC held its stake in shares of Sanofi (NYSE:SNY) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 66,900 shares of the company’s stock at the end of the second quarter. GFS Advisors LLC’s holdings in Sanofi were worth $3,205,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Harbour Capital Advisors LLC bought a new stake in shares of Sanofi during the first quarter valued at $113,000. Eagle Ridge Investment Management bought a new stake in shares of Sanofi during the second quarter valued at $160,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after buying an additional 3,713 shares during the last quarter. Huntington National Bank boosted its stake in shares of Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock valued at $202,000 after buying an additional 147 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in shares of Sanofi by 95.8% in the first quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock valued at $210,000 after buying an additional 2,087 shares during the last quarter. 9.90% of the stock is owned by institutional investors.

Shares of Sanofi (NYSE SNY) opened at 48.71 on Friday. The company’s 50-day moving average price is $47.89 and its 200 day moving average price is $46.63. The firm has a market cap of $122.34 billion, a PE ratio of 11.55 and a beta of 0.88. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24.

Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting analysts’ consensus estimates of $0.74. The company had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, analysts predict that Sanofi will post $3.26 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/25/sanofi-sny-position-maintained-by-gfs-advisors-llc.html.

SNY has been the subject of several recent research reports. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Friday, June 2nd. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Argus increased their price target on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, Cowen and Company reissued a “market perform” rating and issued a $52.00 price target (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $54.00.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.